News
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...
Weight loss drugmaker Novo Nordisk (NVO ... was made in light of the company’s recent market challenges and the performance of its stock since mid-2024. Jørgensen has agreed to serve as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results